RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204

 RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204

RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204

Shots:

  • The companies signed an agreement to manufacture movantik for opioid-induced constipation and RHB-204, currently in a P-III US study as a stand-alone 1L treatment for pulmonary NTM disease
  • Movantik is the leading prescribed oral peripherally acting mu-opioid receptor antagonist (PAMORA) in the US specifically designed to treat OIC in adult patients with chronic non-cancer pain
  • RHB-204 has received FDA Fast Track, OD, and QIDP designations aimed at accelerating development and FDA review and extending the US market exclusivity to a potential total of 12 yrs. (to be granted at the time of FDA approval)

Click here ­to­ read full press release/ article | Ref: RedHill | Image: RedHill

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post